New Issue

November, 2021

We are starting a new issue in November and are looking for SEK 20 million in this first step. The capital injection will be used to carry out several clinical trials, including Phase I. We also intend to be able to prepare for Phase II with these funds. Please contact us for more information. We… Read More »New Issue

New patent application filed

June, 2021

Milmed Unico AB have filed a new patent application the 30th of June. The patent is for Treatment of inflammation. In vitro studies at Sapienza University have given significant results. In vivo studies will be performed and first study will focus on IBS ( Irritable Bowel Syndrome.

New agreement signed with Medicorent

March, 2021

Master agreement signed with Medicorent and Startup Pharma. Medicorent provides CRO and regulatory services. Startup Pharma provides services internationally regarding new establishments of health products and has reputable contacts with companies in several countries.

Production agreement signed with Orkla

January, 2021

Production agreement signed with Orkla (Jästbolaget) and Orkla will produce the dry product on a large scale during Q2.

Allergy patent approved

December, 2020

The Swedish patent application for treatment of allergic disorders is approved, October 7th 2020. SE Pat. Nr.543 316

Published scientific article

November, 2020

An article is published in the scientific journal Journal of Immunology and Allergy. It is about a study of people with various allergic disorders where one group received treatment of treated Milmed, and the other group received untreated Milmed. Scientific article name: Milmed Treatment Alleviates Symptoms of Allergy and Improves General Health